Aclarion Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$4.51next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| CLARITY Trial Public Disclosure of Early Interim Results | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Nociscan Scan Volume Growth (Year-over-Year) Quarterly196.0%
Nociscan Scan Volume Growth (Sequential Quarter-over-Quarter) Quarterly64.0%
CLARITY Trial Patient Enrollment Progress Quarterly0.3
Watch Items
- CLARITY Trial Interim Data ReadoutTrigger: Initial internal readout expected in Q3 2026; public disclosure of early interim results expected in Q4 2026Action: Evaluate clinical efficacy data and surgical success rates to validate Nociscan's utility in guiding treatment decisions.
- U.S. Reimbursement and Payer Coverage DecisionsTrigger: Collaboration with PRIA Healthcare to establish Market Access ProgramAction: Monitor progress of prior authorization support, appeals management, and discussions with commercial insurance carriers for local coverage decisions.
- Unsolicited Acquisition Proposals and Hostile Takeover DefenseTrigger: Rejection of Echo Lake Capital's unsolicited acquisition proposal of $4.00 per shareAction: Track board evaluations of strategic priorities, execution of the $2.5 million share repurchase program, and the stockholder rights agreement.
Research as of 20 Jun 2026